Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
about
Heart Failure with Preserved Ejection Fraction - Concept, Pathophysiology, Diagnosis and Challenges for TreatmentTargeting heart failure with preserved ejection fraction: current status and future prospectsImpact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsBiomarkers in heart failure with preserved ejection fractionBreakthrough in heart failure with preserved ejection fraction: are we there yet?Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic ReviewChallenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"Myocardial hypertrophy and its role in heart failure with preserved ejection fractionExercise intolerance in heart failure with preserved ejection fraction: more than a heart problemHeart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesPatient selection in heart failure with preserved ejection fraction clinical trialsHeart failure with preserved ejection fractionAdvances in the management of heart failure: the role of ivabradineDiagnostic Accuracy of Tissue Doppler Index E/e' for Evaluating Left Ventricular Filling Pressure and Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-AnalysisWhat global diastolic function is, what it is not, and how to measure itDiastolic dysfunctionAngiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyondDiuretics: a review and updateCardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.The clinical epidemiology of fatigue in newly diagnosed heart failure.Advances in the pathophysiology and treatment of heart failure with preserved ejection fractionSkeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction.Developing therapies for heart failure with preserved ejection fraction: current state and future directionsUpdate on heart failure with preserved ejection fraction.Fibrosis quantification in Hypertensive Heart Disease with LVH and Non-LVH: Findings from T1 mapping and Contrast-free Cardiac Diffusion-weighted imagingBeta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary studyCardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis.The continuum of personalized cardiovascular medicine: a position paper of the European Society of CardiologySex- and gender-specific research priorities for the emergency management of heart failure and acute arrhythmia: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research Workgroup.Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and designEffects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials.A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fractionSignificance of AT1 receptor independent activation of mineralocorticoid receptor in murine diabetic cardiomyopathy.Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessonsClinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
P2860
Q26747554-293F43DE-FEBA-4AA5-9784-411F4F04B7B9Q26752956-9E94BB0F-A8CD-4760-81A8-B7667E664334Q26764927-8F2DD910-BFD6-42F2-BF03-85CD4828359AQ26768192-A6F6E0F9-AF1D-4879-B65D-17C4D6128B09Q26771999-57EA415D-A8FE-4C37-AB90-FCF38F12753BQ26783958-3F7D85F3-E2FF-48A5-9CEC-06471504ED02Q26785931-664FF63B-A55B-4641-82F8-430AC40ED954Q26800076-565AAE6F-E5B7-46D1-878A-DA68D23CA9FBQ26991985-B7995C5C-DD8B-47EF-972A-5BD28504A5A1Q27000263-7A7FE48D-418E-4C4E-9DF2-944800AF7A9BQ27015845-4124D727-70FD-4F65-A01E-A14CE1F709B4Q27024008-9D0F25CF-7D04-4C79-B4FB-CF567DBA9C39Q28072418-9E239188-7E5A-4ED0-8C70-D69ECF49670EQ28073894-B0A0454A-3AF0-4645-9BCF-65C0E84321B6Q28087043-DBB353A0-7D26-433F-A404-9C9211D96E10Q28087715-8EEA0EFC-8A6A-41AC-8259-0F05F94E443BQ28088583-606DA418-AB07-41E5-A936-80B1BF608914Q28302157-3F35A33C-C413-470B-ADFB-4FA3128A1B9FQ30833375-11D471C1-EFB7-455A-9A86-733D55A4E6B8Q33168611-C3B46ED6-E477-4C4C-8794-4EEB038E18D1Q33565707-F4B06FF5-9303-4C31-81FB-48C4444C145BQ33568831-33328442-1ADF-4D97-A7A9-91EC362BEF13Q33639223-14EE0923-84AF-47CD-9C1E-5A501722ADF0Q33640339-EB896A5B-BE03-482B-A3A9-5799878D3E38Q33673965-BF98E68D-7211-4C58-A650-3E3CBF8014AFQ33857564-28A57F7B-CC8C-4757-8AC5-61824138C655Q33992679-5147E1DB-066A-40E3-8B3C-84703D44BBDCQ34046332-038F82C7-E4D1-44E4-8A4A-BA3B20ACC09FQ34375466-58DA0135-CF88-4DAE-A1BA-7AA016915135Q34550879-4562C225-45B6-40DE-ACB9-9ADE43487197Q34644992-88CD3277-C807-4CEB-919E-14FCE8569793Q34836591-BB40654B-008A-4610-9A85-FA9C95FEA6D2Q35005829-6467250F-266D-4D83-9AC5-DA2841F36330Q35018046-2A886B1D-B164-4926-A207-6D5617B2B694Q35057999-7052A621-68A6-4825-BDCE-557F383A9489Q35130314-56F36871-CB67-4332-8186-54A41E3CA4CCQ35139959-6E60D97A-5208-42CE-8D4B-331904E04FDCQ35738903-CFEDE801-02DA-49C6-B123-E96458F3D176Q35743444-7D43C9FC-30D8-45F9-8640-56BF40BF363CQ35921040-3DAB71F2-406C-4EE6-B6D3-063E452B39BD
P2860
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effect of spironolactone on di ...... F randomized controlled trial.
@en
type
label
Effect of spironolactone on di ...... F randomized controlled trial.
@en
prefLabel
Effect of spironolactone on di ...... F randomized controlled trial.
@en
P2093
P50
P921
P356
P1476
Effect of spironolactone on di ...... F randomized controlled trial.
@en
P2093
Albrecht G Schmidt
Aldo-DHF Investigators
André Duvinage
Carsten Tschöpe
Caterina Colantonio
Elisabeth Kraigher-Krainer
Frank Edelmann
Götz Gelbrich
Hans-Dirk Düngen
Kathleen Durstewitz
P304
P356
10.1001/JAMA.2013.905
P407
P577
2013-02-01T00:00:00Z